precisionmedicineonline23h
Restore Vision Doses First Retinitis Pigmentosa Patient in Phase I/II Gene Therapy Trial
The Tokyo-based biotech firm expects RV-001 to be able to alter light sensitivity for patients with limited or no vision regardless of genotype.
BMJ14h
AB0285 EFFECTIVENESS OF IMMUNOSUPPRESSIVE THERAPY FOR CONNECTIVE TISSUE DISEASE–ASSOCIATED PULMONARY ARTERIAL HYPERTENSION
Two patients (15%) died during maintenance therapy for causes other than PAH. Three-year and five-year survival rates were 91.7% and 81.5%, respectively. Conclusion: IT without titration of pulmonary ...